Journal Watch · Journal for ImmunoTherapy of Cancer · 2026

RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs.

Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.

Ibanez-Vega J, Teis R, Ocasio JK et al.Journal for ImmunoTherapy of Cancer3 min readPharma relevance 50/100

DOI: 10.1136/jitc-2025-013134PMID: 41912267Study type: in-vitro / cell study

TL;DR

Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.

Key findings

  • RASA2-deleted CAR T-cells exhibited enhanced calcium flux, increased accumulation of activated signaling molecules and lytic granules at the synapse, and increased actin cytoskeleton dynamics, which produced larger synaptic areas and resulted in enhanced migration ex vivo.
  • Further, RASA2-deleted CAR T-cells demonstrated improved in vitro functionality and superior early in vivo anti-tumor responses against DMGs compared with controls.<h4>Conclusions</h4>Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells.
  • Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.

What they did

Lastly, we genetically deleted <i>RASA2</i>, a negative regulator of T cell activation, and evaluated the resulting impact on IS formation and quality, as well as in vitro and in vivo functionality.<h4>Results</h4>We show that limited efficacy of B7-H3 CAR T-cells is due to DMG-mediated inefficient interaction between CAR T-cells and DMG cells. Specifically, DMG cells impair the IS formation, resulting in poor CAR T-cell activation, cytokine secretion, and limited anti-tumor response in vivo. RASA2 deletion improved CAR T-cell activation through the formation of a more functional IS.

Full abstract (original)

Background: <h4>Background</h4>Chimeric antigen receptor (CAR) T-cell therapy has demonstrated safety and modest efficacy against diffuse midline gliomas (DMGs), a highly aggressive pediatric brain tumor. However, mechanisms of CAR T-cell resistance in DMG settings remain unknown.<h4>Methods</h4>We compared the efficacy of B7-H3 CAR T-cells between SJ-DIPGX7c (DMG) and U87-MG (adult glioblastoma) patient-derived cell lines and showed impaired efficacy both in vitro and in vivo. We performed live-cell imaging and single-cell RNA sequencing to investigate deficiencies in immune synapse (IS) formation between CAR T-cells and DMGs.

What they did: Lastly, we genetically deleted <i>RASA2</i>, a negative regulator of T cell activation, and evaluated the resulting impact on IS formation and quality, as well as in vitro and in vivo functionality.<h4>Results</h4>We show that limited efficacy of B7-H3 CAR T-cells is due to DMG-mediated inefficient interaction between CAR T-cells and DMG cells. Specifically, DMG cells impair the IS formation, resulting in poor CAR T-cell activation, cytokine secretion, and limited anti-tumor response in vivo. RASA2 deletion improved CAR T-cell activation through the formation of a more functional IS.

Results & conclusions: RASA2-deleted CAR T-cells exhibited enhanced calcium flux, increased accumulation of activated signaling molecules and lytic granules at the synapse, and increased actin cytoskeleton dynamics, which produced larger synaptic areas and resulted in enhanced migration ex vivo. Further, RASA2-deleted CAR T-cells demonstrated improved in vitro functionality and superior early in vivo anti-tumor responses against DMGs compared with controls.<h4>Conclusions</h4>Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells. Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.

Abstract © the authors / Journal for ImmunoTherapy of Cancer (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1136/jitc-2025-013134 · PubMed 41912267.

Why it matters for pharma & biotech

  • Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: cell therapy (CAR-T / engineered cells)

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal for ImmunoTherapy of Cancer study find?

Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.

What type of study is this?

It is a in-vitro / cell study, published in Journal for ImmunoTherapy of Cancer in 2026. Lastly, we genetically deleted <i>RASA2</i>, a negative regulator of T cell activation, and evaluated the resulting impact on IS formation and quality, as well as in vitro and in vivo functionality.<h4>Results</h4>We show that limited efficacy of B7-H3 CAR T-cells is due to DMG-mediated inefficient interaction between CAR T-cells and DMG cells.

Where can I read the original paper?

The original is at the publisher via DOI 10.1136/jitc-2025-013134. PubMed ID: 41912267. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ibanez-Vega J, Teis R, Ocasio JK et al.. RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs.. Journal for ImmunoTherapy of Cancer (2026). DOI: 10.1136/jitc-2025-013134.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/rasa2-deletion-rescues-immune-synapse-dysfunction-enhancing-car-t-cell-e-013134/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides